Year All202620252024202320222021202020192018201720162015201420122011 Sep 17, 2019 Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 12, 2019 Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Sep 3, 2019 Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Sep 2, 2019 Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Aug 9, 2019 Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights May 30, 2019 Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference May 7, 2019 Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Mar 14, 2019 Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors Mar 7, 2019 Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology Mar 6, 2019 Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights